605033.SHG Shaanxi Meibang Pharmaceutical Group Co Ltd
- Market cap
- CNY 2.32B
- P/E
- 36.6x
- P/B
- 1.90x
- ROE
- 5.8%
- Dividend yield
- 1.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 605033.SHG undervalued?
Graham number605033.SHG trades 75.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shaanxi Meibang Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Shaanxi Meibang Pharmaceutical Group Co Ltd yet.
Shaanxi Meibang Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shaanxi Meibang Pharmaceutical Group Co Ltd
Shaanxi Meibang Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, sale, and agricultural technology promotion, and service of pesticide products in China and internationally. The company offers pesticides, plant nutrients, fungicides, insecticides, acaricides, herbicides, plant growth regulators, fertilizers, and microbial fertilizers. It is also involved in sale of agricultural machinery. The company was fou…
Full company profileShaanxi Meibang Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shaanxi Meibang Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 422M | 439M | 516M | 569M | 842M | 906M | 699M | 886M | 912M | 933M |
| Gross Profit | 149M | 155M | 190M | 200M | 310M | 377M | 221M | 231M | 312M | 353M |
| Operating Income | 69.9M | 66.9M | 86.0M | 87.6M | 123M | 140M | 50.4M | 30.6M | 64.8M | 105M |
| EBITDA | 79.6M | 79.9M | 98.6M | 101M | 155M | 169M | 83.8M | 58.3M | 85.4M | 87.4M |
| Net Income | 61.2M | 59.3M | 76.3M | 78.7M | 126M | 145M | 57.6M | 36.9M | 48.7M | 69.3M |
| EPS | 0.68 | 0.63 | 0.77 | 0.78 | 1.14 | 1.07 | 0.43 | 0.27 | 0.36 | 0.51 |
| Balance Sheet | ||||||||||
| Total Assets | 510M | 586M | 666M | 786M | 1.46B | 1.56B | 1.69B | 1.86B | 2.07B | 1.93B |
| Total Liabilities | 329M | 309M | 295M | 337M | 496M | 474M | 578M | 737M | 915M | 737M |
| Shareholders' Equity | 180M | 276M | 371M | 449M | 967M | 1.09B | 1.11B | 1.12B | 1.15B | 1.19B |
| Cash & Short-term Investments | 43.2M | 70.3M | 220M | 199M | 402M | 398M | 481M | 656M | 338M | 222M |
| Total Debt | 49.0M | 27.0M | 40.0M | 59.9M | 27.1M | 106M | 1.00M | 72.0M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 29.4M | 17.0M | 128M | 74.9M | -109M | 126M | 335M | 280M | 229M | - |
| Capital Expenditure | 17.6M | 34.9M | 33.8M | 61.7M | 107M | 109M | 204M | 159M | 185M | 124M |
| Free Cash Flow | 11.8M | -17.9M | 94.7M | 13.2M | -215M | 17.1M | 131M | 122M | 44.7M | -297M |
| Ratios | ||||||||||
| ROE | 33.9% | 21.5% | 20.6% | 17.5% | 13.0% | 13.4% | 5.2% | 3.3% | 4.2% | 5.8% |
| ROA | 12.0% | 10.1% | 11.5% | 10.0% | 8.6% | 9.3% | 3.4% | 2.0% | 2.4% | 3.6% |
| Net Profit Margin | 14.5% | 13.5% | 14.8% | 13.8% | 14.9% | 16.0% | 8.2% | 4.2% | 5.3% | 7.4% |
| Debt to Equity | 0.27x | 0.10x | 0.11x | 0.13x | 0.03x | 0.10x | 0.00x | 0.06x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shaanxi Meibang Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 1.04%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 49.5%
- Ex-dividend date
- Nov 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 24.1M | 0.18 | 49.5% |
| 2024 | CNY 28.2M | 0.21 | 76.6% |
| 2023 | CNY 29.7M | 0.22 | 51.7% |
| 2022 | CNY 25.7M | 0.19 | 17.7% |
| 2021 | CNY 3.29M | 0.03 | 2.6% |
| 2020 | CNY 699K | 0.01 | 0.9% |
| 2019 | CNY 2.07M | 0.02 | 2.7% |
| 2018 | 3.58M | 0.04 | 6.0% |
| 2017 | 3.60M | 0.04 | 5.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shaanxi Meibang Pharmaceutical Group Co Ltd
- Insiders 72.04%
- Institutions 1.72%
- Public & others 26.24%
- Shares outstanding 135M
- Free float 32.7M
Shaanxi Meibang Pharmaceutical Group Co Ltd company profile
- Company name
- Shaanxi Meibang Pharmaceutical Group Co Ltd
- Ticker
- 605033.SHG
- ISIN
- CNE100005071
- Exchange
- Shanghai Stock Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 1,117
- Fiscal year end
- December
- Address
- Shiyang Industrial Park, Xi'an, China, 710018
- Phone
- 86 29 8668 0383
- Website
- meibang.cn
About Shaanxi Meibang Pharmaceutical Group Co Ltd
Shaanxi Meibang Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, sale, and agricultural technology promotion, and service of pesticide products in China and internationally. The company offers pesticides, plant nutrients, fungicides, insecticides, acaricides, herbicides, plant growth regulators, fertilizers, and microbial fertilizers. It is also involved in sale of agricultural machinery. The company was founded in 1998 and is headquartered in Xi'an, China.
Shaanxi Meibang Pharmaceutical Group Co Ltd management
5- Mr. Tong ZhangGM & Director · born 1993
- Ms. Meixi HeAccounting Supervisor & CFO · born 1967
- Ms. Lijuan HanDeputy GM & Director · born 1978
- Mr. Mingyu QiaoDeputy General Manager · born 1977
- Ms. Aixiang ZhaoCompany Secretary · born 1969